Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466687 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
A Phase 2 study of Melanoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 4
- Study locations
NCT00466687 is a Phase 2 study of Melanoma that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 34 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT00466687, a Phase 2 study of Melanoma, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IV melanoma.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- BIOLOGICAL bevacizumab
- DRUG erlotinib hydrochloride
- GENETIC fluorescence in situ hybridization
- OTHER immunologic technique
Study Locations (4)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Sarah Cannon Research Institute - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00466687
The ClinicalTrials.gov registry entry for NCT00466687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00466687 reports 4 study locations spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00466687 about?
NCT00466687 is a clinical study titled "Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them o...
What is the current status of trial NCT00466687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2004-09. Estimated completion is 2008-09.
What conditions does trial NCT00466687 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00466687?
The interventions under investigation include: gene expression analysis (GENETIC), bevacizumab (BIOLOGICAL), erlotinib hydrochloride (DRUG), fluorescence in situ hybridization (GENETIC), immunologic technique (OTHER).
Who is sponsoring clinical trial NCT00466687?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00466687 being conducted?
This trial has 4 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.